New indication for Eylea
Eylea (aflibercept; Bayer) is now indicated for visual impairment due to myopic choroidal neovascularisation. Further changes to the summary of product characteristics reflect this addition.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200074
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now